C042P: Clenoliximab Biosimilar, CD4 Monoclonal Antibody
Recombinant Humanized IgG4 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade clenoliximab biosimilar specifically binds to the human CD4.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by clenoliximab.BP4091: In Vivo Grade Recombinant Human IgG1 Fc protein (hIgG1 Fc)
The recombinant human IgG1 Fc protein was produced in mammalian cells and purified by protein A.
Purity: >95% by SDS-PAGE under reducing conditions
Endotoxin: Less than 1 EU/mg of protein as determined by LAL method.Recombinant human IgG1 Fc protein mutants available including hIgG1 Fc C103S; hIgG1 Fc D265A; hIgG1 Fc R214K; hIgG1 Fc R214K/N297A; hIgG1 Fc L234A/L235A; hIgG1 Fc L234F/L235E/P331S; hIgG1 Fc L235A/G237A. Recombinant human IgG1 isotype control antibody and mutants are available. Biotinylated hIgG1 Fc, and hIgG1 Fc with Avi-, His-, and DYKDDDDK-tags are also available.